Parameter | Value for the group^{a} | P value^{b} | |
---|---|---|---|

Combo (n = 50) | VAN alone (n = 30) | ||

Median VAN MIC (mg/liter [IQR])^{c} | 2.0 (1.5–2.0) | 1.5 (1.5–2.0) | 0.066^{d} |

MRSA strain^{d} | 0.213 | ||

USA100 | 17 (35.4) | 14 (50.0) | |

USA300 | 31 (64.6) | 14 (50.0) | |

agr functionality^{e} | 0.764 | ||

Functional | 31 (75.6) | 21 (72.4) | |

Loss of function | 10 (24.4) | 8 (27.6) | |

agr group^{f} | 0.943 | ||

Group I | 29 (59.2) | 18 (60.0) | |

Group II | 20 (40.8) | 12 (40.0) |

↵a Except where otherwise noted, data are expressed as number (percentage) of patients.

↵b

*P*values were calculated by the likelihood ratio χ^{2}test, except where otherwise noted.↵c Vancomycin Etest MIC. IQR, interquartile range.

↵d Wilcoxon rank sum test.

↵e MRSA strain type and

*agr*were not available for all isolates.↵f One patient in the Combo group had an isolate from

*agr*group III and was not included in this analysis.